# Food and Drug Administration

Type: organization

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/food-and-drug-administration
Canonical HTML page: https://getlegalbrief.com/entity/food-and-drug-administration

## Timeline

- **2026-02-03**: Refusal to File — FDA's Vinay Prasad issues a formal refusal to review the flu vaccine application.
- **2025-11-10**: Grant Rescissions — The White House rescinds hundreds of millions in mRNA research funding.
- **2025-08-20**: Workaround Support — FDA officials reportedly signal acceptance of Moderna's alternative trial data submission.
- **2024-01-15**: Flu Vaccine Collaboration — Moderna begins working with the FDA on trial designs for its mRNA flu vaccine.
- **2021-08-01**: Peak Valuation — Moderna reaches a $200 billion market cap following global vaccine success.

## Recent coverage (2 stories)

### GOP's 'Clean Water For All Life Act' Targets Abortion Pills via EPA Regulation
2026-03-20 00:33:18 · Sentiment: Bearish · Impact: 6/10 · Sources: 3

House Republicans have introduced legislation that would criminalize flushing fetal remains, mandating the use of 'catch kits' for medical abortions to prevent alleged water contamination. The bill represents a novel attempt to use environmental protection frameworks to restrict reproductive healthcare access and ban telehealth services.
Full story: https://getlegalbrief.com/story/gop-clean-water-act-abortion-pill-regulation

### FDA Regulatory Shifts and Moderna's Flu Vaccine Setback Threaten Innovation
2026-03-16 00:09:34 · Sentiment: Bearish · Impact: 8/10 · Sources: 2

The FDA's rare 'refusal to file' regarding Moderna's mRNA flu vaccine signals a pivot from pandemic-era collaboration to a more adversarial regulatory environment. This unpredictability, combined with rescinded federal grants and a 90% decline in market value, highlights the growing legal and compliance risks for biotech firms.
Full story: https://getlegalbrief.com/story/fda-moderna-regulatory-risk-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.